- Home
- IDA vs NUVL Comparison
IDA vs NUVL Comparison
Compare IDA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDA
- NUVL
- Stock Information
- Founded
- IDA 1915
- NUVL 2017
- Country
- IDA United States
- NUVL United States
- Employees
- IDA N/A
- NUVL N/A
- Industry
- IDA Electric Utilities: Central
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- IDA Utilities
- NUVL Health Care
- Exchange
- IDA Nasdaq
- NUVL Nasdaq
- Market Cap
- IDA 6.1B
- NUVL 5.6B
- IPO Year
- IDA N/A
- NUVL 2021
- Fundamental
- Price
- IDA $114.09
- NUVL $65.15
- Analyst Decision
- IDA Buy
- NUVL Strong Buy
- Analyst Count
- IDA 6
- NUVL 10
- Target Price
- IDA $120.50
- NUVL $113.10
- AVG Volume (30 Days)
- IDA 315.8K
- NUVL 588.4K
- Earning Date
- IDA 05-01-2025
- NUVL 05-08-2025
- Dividend Yield
- IDA 2.85%
- NUVL N/A
- EPS Growth
- IDA 7.00
- NUVL N/A
- EPS
- IDA 5.50
- NUVL N/A
- Revenue
- IDA $1,826,633,000.00
- NUVL N/A
- Revenue This Year
- IDA $8.34
- NUVL N/A
- Revenue Next Year
- IDA $7.28
- NUVL N/A
- P/E Ratio
- IDA $21.95
- NUVL N/A
- Revenue Growth
- IDA 3.41
- NUVL N/A
- 52 Week Low
- IDA $88.70
- NUVL $61.80
- 52 Week High
- IDA $120.85
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- IDA 66.61
- NUVL 32.14
- Support Level
- IDA $111.41
- NUVL $67.47
- Resistance Level
- IDA $120.84
- NUVL $77.93
- Average True Range (ATR)
- IDA 1.79
- NUVL 3.14
- MACD
- IDA 0.45
- NUVL -0.71
- Stochastic Oscillator
- IDA 88.07
- NUVL 7.83
About IDA IDACORP Inc.
Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.